cervical cancer Apr 5, 2022 Nurix Therapeutics Doses First Gynecologic Cancer Patient in Modified Autologous TIL Trial Mar 28, 2022 EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in PD-L1-Expressing Cervical Cancers Feb 11, 2022 Nykode Therapeutics Completes Enrollment for HPV16-Positive Cervical Cancer Vaccine Trial Oct 13, 2021 FDA Approves First-Line Keytruda Combo for PD-L1-Expressing Cervical Cancer Patients Mar 23, 2021 European Consortium Wins €6.9M Grant to Develop HPV16-Positive Cancer Vaccine Feb 24, 2021 Qiagen, Inovio Expand CDx Partnership, Starting With NGS Test for Cervical Dysplasia Therapy Feb 5, 2021 With First-In-Class Iovance BLA Pending, TIL Therapies on Cusp of Commercialization Premium Oct 12, 2020 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test Sep 16, 2020 FDA Approves Expanded Use for Roche Cytology Test in Patients With Cervical Cancer Aug 31, 2020 Precigen Testing Whether its Vaccine Can Raise T-Cell Army Against HPV-Positive Cancers Premium Aug 3, 2020 Puma's Nerlynx Offers Targeted Treatment Opportunity for HER2-Mutant Cervical Cancer in Basket Trial Premium Apr 17, 2019 FDA Approves Expanded Use of Agilent CDx for Keytruda in Lung Cancer Aug 21, 2018 FDA Approves Expanded Use of Agilent Assay as Keytruda CDx for Urothelial Cancer Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
